Joseph Burnett, CEO and President of ClearPoint Neuro, Inc. (NASDAQ:CLPT), filed a Form 4 on September 3, 2026, reporting the exercise of stock options and resulting changes in beneficial ownership as of September 2, 2026.

Key Highlights

  • Options exercised: Burnett exercised stock options covering 12,517 shares of common stock at an exercise price of $3.47 per share on September 2, 2026.
  • Payment in cash: According to the filing, Burnett paid the exercise price in cash and retained all shares received upon exercise, with no shares sold in connection with the transaction.
  • Direct holdings after transaction: Following the exercise, Burnett directly holds 130,720 shares of common stock.
  • Indirect holdings: An additional 191,388 shares are held indirectly through the Joseph M. Burnett Trust dated 10/20/2022, of which Burnett serves as trustee.
  • Remaining options: Burnett retains 61,887 stock options (right to buy) with an exercise price of $3.47 and an expiration date of August 15, 2029.

ClearPoint Neuro CEO Burnett Reports Option Exercise and Beneficial Ownership Update

The Form 4 filed by Joseph Burnett, who serves as both a Director and CEO and President of ClearPoint Neuro, Inc., discloses a transaction coded "M," indicating the exercise of a derivative security. On September 2, 2026, Burnett acquired 12,517 shares of common stock through the exercise of stock options at a price of $3.47 per share. The filing states that the exercise price was paid in cash and that all shares received were retained, with no shares disposed of in connection with the transaction.

The options exercised were granted on August 15, 2019, and according to the filing, vested as follows: 20% on the first anniversary of the grant date, 40% on the second anniversary, and 40% on the third anniversary. The expiration date for the options is August 15, 2029. Following this exercise, Burnett's direct beneficial ownership of common stock stands at 130,720 shares. Burnett also holds 191,388 shares indirectly through the Joseph M. Burnett Trust dated 10/20/2022, of which he serves as trustee.

After the reported transaction, 61,887 stock options remain held directly by Burnett. The Form 4 was signed by Danilo D'Alessandro pursuant to a power of attorney on behalf of Joseph M. Burnett on September 2, 2026.

What Was Disclosed

The filing reports the exercise of 12,517 stock options at $3.47 per share by ClearPoint Neuro's CEO, with all resulting shares retained. Direct holdings following the transaction total 130,720 shares, and indirect trust holdings total 191,388 shares.